
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc is positioned favorably in the oncology market with its unique MasterKey therapies targeting families of oncogenic mutations, including drugs such as BDTX-4933 and BDTX-1535, which are designed to improve patient outcomes. The company's upcoming catalysts, particularly in the assessment of acute loss of treatment durability measures and overall response rates, are anticipated to significantly increase projected sales to between $500 million and $750 million by 2026, suggesting substantial revenue potential. Additionally, Black Diamond's demonstrated efficacy, especially with the silevertinib drug, highlights a promising viability in key treatment areas, which could command a considerable market share, enhancing the company's financial outlook and growth prospects.
Bears say
The analysis indicates concerns regarding the replicability of reported efficacy results for Black Diamond Therapeutics' drug silevertinib, as a lower dosage raises doubts about its overall effectiveness, reflected by a correlation with significantly adjusted probabilities of success. Comparatively, its clinical response rate (cORR) in certain subsets is underwhelming when measured against competitors, notably fimoterinib, which may undermine silevertinib's market potential. Additionally, the company's current market capitalization of approximately $230 million suggests investor skepticism surrounding silevertinib's competitiveness in the 1L EGFR-NCM patient population, particularly if future trials reveal less favorable outcomes.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares